Jefferies upgraded Insulet Corporation (NASDAQ:PODD) to a "Buy" rating with a new price target of $400, indicating a positive outlook on the company's future.Insulet reported earnings per share of $1.24 for Q3 2025, surpassing estimates and showing a significant year-over-year increase.The company's revenue reached $706.3 million for the quarter, driven by high demand for its innovative wearable insulin pumps.On November 6, 2025, Jefferies upgraded Insulet Corporation's stock (NASDAQ:PODD) to a "Buy" rating ...